MATINAS BIOPHARMA HOLDINGS, INC.

(MTNB)
  Report
Delayed Nyse  -  05/27 04:00:00 pm EDT
0.7500 USD    0.00%
05/12TRANSCRIPT : Matinas BioPharma Holdings, Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12MATINAS BIOPHARMA HOLDINGS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
05/12Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highlights
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Matinas BioPharma Says Data Monitoring Panel Backs Continuation of Meningitis Trial to Final Patient Cohort

12/16/2021 | 07:36am EDT


© MT Newswires 2021
All news about MATINAS BIOPHARMA HOLDINGS, INC.
05/12TRANSCRIPT : Matinas BioPharma Holdings, Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12MATINAS BIOPHARMA HOLDINGS, INC. : Results of Operations and Financial Condition, Regulati..
AQ
05/12Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highligh..
GL
05/12Matinas BioPharma Reports First Quarter 2022 Financial Results and Operational Highligh..
GL
05/12Note 2 - Liquidity and Plan of Operations
AQ
05/12Matinas BioPharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended M..
CI
05/05Matinas BioPharma to Webcast Conference Call Discussing First Quarter 2022 Financial an..
GL
05/03Matinas BioPharma to Present at the 12th Annual BioNJ BioPartnering Conference
GL
05/03Matinas BioPharma to Present at the 12th Annual BioNJ BioPartnering Conference
AQ
04/13MATINAS BIOPHARMA HOLDINGS, INC. : Regulation FD Disclosure (form 8-K)
AQ
More news
Analyst Recommendations on MATINAS BIOPHARMA HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 0,01 M - -
Net income 2022 -27,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,77x
Yield 2022 -
Capitalization 163 M 163 M -
Capi. / Sales 2022 20 331x
Capi. / Sales 2023 21 401x
Nbr of Employees 31
Free-Float 97,1%
Chart MATINAS BIOPHARMA HOLDINGS, INC.
Duration : Period :
Matinas BioPharma Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,75 $
Average target price 2,75 $
Spread / Average Target 267%
EPS Revisions
Managers and Directors
Jerome D. Jabbour President, Chief Executive Officer & Director
Keith A. Kucinski Chief Financial Officer
Herbert J. Conrad Chairman
Raphael J. Mannino Chief Scientific Officer & Senior Vice President
James J. Ferguson Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MATINAS BIOPHARMA HOLDINGS, INC.-25.74%163
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478